This article aims to direct some interest on the positive role that Indomethacin could play in COVID-19. We relied on available evidence from the present literature and results of few clinical trials. We first discussed briefly, the documented antiviral activityof Indomethacin on coronaviruses and other viruses then moved to talk abouthow it could control the exaggerated immune responsefrequently reported during SARS-CoV-2infectionthrough the modulation ofthe PPAR-γ & HIF-1α axis. At the end, we posted the results of some clinical trials that we consider promising.Itisimportant to note that our article does not carry a specificrecommendation forIndomethacinas a global treatment for COVID-19, but we do believe it deservesto be implemented in more clinical trials.
Author and article information
] Bachelor of Pharmacy, the British University in Egypt (BUE)
] Faculty of Medicine, Al-Azhar University for Girls, Cairo, Egypt
This work has been published open access under Creative Commons Attribution License
CC BY 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided
can be found at
Data availability: Data sharing not applicable to this article as no datasets were generated or analysed during the current study.